STOCK TITAN

CIBUS INC SEC Filings

CBUS Nasdaq

Welcome to our dedicated page for CIBUS SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Tracking Cibus Inc.’s leap from lab discovery to licensed crop trait often means sifting through hundreds of pages of technical language. Annual reports detail complex gene-editing pipelines, non-GMO regulatory paths, and royalty economics—yet they rarely answer questions in plain English. If you’ve ever searched for “Cibus SEC filings explained simply,” “Cibus insider trading Form 4 transactions,” or a “Cibus annual report 10-K simplified,” you know the challenge.

Stock Titan removes that friction. Our AI-powered summaries translate each section of the Cibus annual report into concise language, linking risk factors to revenue streams. The platform delivers the latest “Cibus quarterly earnings report 10-Q filing,” complete with side-by-side R&D versus cash-burn charts, and a dedicated module for “Cibus earnings report filing analysis.” Real-time alerts capture every “Cibus Form 4 insider transactions real-time,” so you can monitor Cibus executive stock transactions Form 4 before markets open. Need context on regulatory milestones? We tag each “Cibus 8-K material events explained” entry with potential impacts on trait licensing revenue.

Investors use these tools to answer practical questions:

  • How do Rapid Trait Development System costs trend quarter over quarter?
  • Which officers exercised options ahead of a new canola trait announcement?
  • What bonuses are disclosed in the Cibus proxy statement executive compensation?
With comprehensive coverage of all forms—10-K, 10-Q, 8-K, DEF 14A, and more—plus on-demand explanations, understanding Cibus SEC documents with AI becomes routine. No more hunting; the insights arrive the moment filings hit EDGAR.

Rhea-AI Summary

Cibus, Inc. (CBUS) reported an equity award to a company director. On 11/05/2025, the director received a stock option45,627 shares of Class A common stock at an exercise price of $1.32 per share. The option becomes exercisable on 05/22/2026 and expires on 11/05/2035, with no purchase price paid for the option itself. Following this grant, the director beneficially owns 45,627 derivative securities directly.

The option vests, subject to continued board service, on the earlier of the first anniversary of the grant date or the company’s next annual shareholder meeting. Any remaining unvested portion will fully vest if a defined Triggering Event under the company’s 2017 Omnibus Incentive Plan occurs while the director continues to serve.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cibus, Inc. filed an initial ownership report for director Craig Wichner. The Form 3 indicates that, as of the event date of 11/05/2025, he beneficially owns 0 shares of Cibus Class A Common Stock in direct form. The filing also shows no reportable derivative securities, meaning there are no listed options, warrants, or other convertible instruments tied to Cibus stock for this reporting person at this time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cibus, Inc. filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Revenue was $615 thousand for the quarter and $2.6 million year‑to‑date, reflecting limited current commercialization. Quarterly net loss was $24.3 million; year‑to‑date net loss was $100.3 million.

Cash and cash equivalents were $23.9 million as of September 30, 2025, against $20.6 million in current liabilities. Management states that additional capital will be needed within a year to support plans. The company raised net proceeds of approximately $21.4 million in January 2025 and $25.0 million in June 2025 follow‑on offerings and terminated its prior ATM facility without 2025 sales.

Year‑to‑date operating expenses totaled $77.5 million, including a $20.9 million goodwill impairment recognized in Q1. A July workforce reduction of ~34 roles incurred $0.2 million in severance in Q3. As of November 10, 2025, the company reported 54,283,111 shares outstanding across Class A and Class B.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
quarterly report
Rhea-AI Summary

Cibus, Inc. reported its results for the three months ended September 30, 2025 and provided a year‑to‑date business update. The company furnished a press release with details as Exhibit 99.1.

The information was furnished under Item 2.02 and is not deemed “filed” under the Exchange Act, limiting its use for liability purposes unless specifically incorporated by reference. The report was signed by Interim Chief Executive Officer Peter Beetham on November 13, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.41%
Tags
current report
-
Rhea-AI Summary

Cibus, Inc. (CBUS) appointed Craig Wichner to its Board of Directors, effective November 5, 2025, and named him to the Board’s Strategy Committee.

Wichner is the Founder and Managing Partner of Farmland LP, a U.S. farmland investment manager with more than $350 million in assets and over 19,000 acres under management. His annual director compensation includes a $60,000 cash retainer (payable semi-annually) and equity with a grant date value of $90,000, prorated for the remainder of fiscal 2025, subject to Board approval under the company’s 2017 Omnibus Incentive Plan. He also entered into the company’s standard indemnification agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Kimberly A. Box, a director of Cibus, Inc. (CBUS), was granted a stock option on 09/11/2025 to purchase 54,722 shares of Class A common stock at an exercise price of $1.40 per share. The option vests on the earlier of the first anniversary of the grant date or the company’s next annual shareholders meeting, subject to continued service, and becomes exercisable beginning 09/11/2026 with an expiration date of 09/11/2035. The filing reports direct beneficial ownership of 54,722 shares following the grant. The grant includes standard acceleration on a defined Triggering Event per the company’s 2017 Omnibus Incentive Plan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Cibus, Inc. (CBUS) Form 3 filed by Kimberly A. Box discloses her role as a director and reports zero shares of Class A common stock and no derivative securities as of the 09/11/2025 event date. The filing is an initial beneficial-ownership statement and was signed by an attorney-in-fact on 09/26/2025. The disclosure documents the absence of direct equity holdings by this reporting director.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cibus, Inc. disclosed an Executive Employment Agreement appointing Cornelis (Carlo) Broos as Chief Financial Officer effective September 18, 2025 (agreement dated September 19, 2025). The agreement is at-will but provides severance protections: 18 months of continued base salary if the company terminates him without Cause or he leaves for Good Reason; and enhanced 24-month severance plus a lump-sum bonus equal to his target annual bonus (or a projected portion if termination occurs in the second half of the fiscal year) and full vesting of unvested equity if termination happens in connection with a Change in Control. Severance payments require customary release delivery. For tax efficiency, about half of Mr. Broos’ compensation will be paid to a Belgian entity wholly owned by him. The filing notes no family relationships or other arrangements related to the appointment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Cibus, Inc. notified the appointment and compensation terms for non-employee director Ms. Box. The Board adopted a Non-Employee Director Compensation Policy providing Ms. Box an annual cash retainer of $60,000 payable semi-annually and equity compensation with a grant-date value of $90,000 to be issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, as amended. The award will be prorated to reflect Ms. Box's service for the remainder of the 2025 fiscal year. The filing is signed by Peter Beetham, Ph.D., Interim Chief Executive Officer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 2,540,536 shares of Cibus, Inc. Class A common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises shared voting and dispositive power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported to share voting and dispositive power. The Master Fund disclaims direct beneficial ownership by reason of the management agreement. The filing states the holdings are owned in the ordinary course of business and not for the purpose of changing or influencing control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
other

FAQ

What is the current stock price of CIBUS (CBUS)?

The current stock price of CIBUS (CBUS) is $1.7 as of December 26, 2025.

What is the market cap of CIBUS (CBUS)?

The market cap of CIBUS (CBUS) is approximately 92.2M.
CIBUS INC

Nasdaq:CBUS

CBUS Rankings

CBUS Stock Data

92.24M
35.09M
33.53%
29%
2.37%
Biotechnology
Agricultural Chemicals
Link
United States
SAN DIEGO